Cancer Care


STEAM (Sequencing Triplet with Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
Principal Investigator (?)
Study Number
This randomized, open-label, multicenter study will evaluate the efficacy and sa fety of FOLFOXIRI/Avastin (bevacizumab) regimens (concurrent and sequential) ver sus FOLFOX/Avastin in first-line in patients with metastatic colorectal cancer. Patients will be randomized to receive Avastin 5 mg/kg intravenously every 2 wee ks with either concurrent or sequential FOLFOXIRI or with FOLFOX for 4 to 6 mont hs of induction therapy, followed by maintenance therapy with Avastin plus eithe r leucovorin/5-fluorouracil or capecitabine until disease progression occurs. Af ter disease progression, patients will receive treatment with a fluoropyrimidine -based chemotherapy plus Avastin. 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.